Guoqin Yu1, Doug Fadrosh, Bing Ma, Jacques Ravel, James J Goedert. 1. aInfections and Immunoepidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda bInstitute of Genomic Sciences, University of Maryland School of Medicine, Baltimore, Maryland, USA.
Abstract
OBJECTIVE: Because differences in anal microbial populations (microbiota) could affect acquisition of HIV or other conditions, especially among MSM, we profiled the microbiota of the anal canal, assessed its stability, and investigated associations with diversity and composition. DESIGN: Microbiota profiles in anal swabs collected from 76 MSM (52 in 1989, swab-1; 66 1-5 years later, swab-2) were compared by HIV status (25 HIV-positive), T-cell subsets, and questionnaire data. METHODS: Bacterial 16S rRNA genes were amplified, sequenced (Illumina MiSeq), and clustered into species-level operational taxonomic units (QIIME and Greengenes). Regression models and Wilcoxon tests were used for associations with alpha diversity (unique operational taxonomic units, Shannon's index). Composition was compared by Adonis (QIIME). RESULTS: Most anal bacteria were Firmicutes (mean 60.6%, range 21.1-91.1%) or Bacteroidetes (29.4%, 4.1-70.8%). Alpha diversity did not change between the two swabs (N = 42 pairs). In swab-2, HIV-positives had lower alpha diversity (P ≤ 0.04) and altered composition, with fewer Firmicutes and more Fusobacteria taxa (P ≤ 0.03), not completely attributable to very low CD4(+) cell count (median 232 cells/μl), prior AIDS clinical diagnosis (N = 17), or trimethoprim-sulfamethoxazole use (N = 6). Similar but weaker differences were observed in swab-1 (HIV-positive median 580 CD4(+) cells/μl; no trimethoprim-sulfamethoxazole). Associations with T-cell subsets, smoking, and sexual practices were null or inconsistent. CONCLUSIONS: The anal microbiota of MSM was relatively stable over 1-5 years. However, with uncontrolled, advanced HIV infection, the microbiota had altered composition and reduced diversity partially attributable to antibiotics. Investigations of microbial community associations with other immune perturbations and clinical abnormalities are needed.
OBJECTIVE: Because differences in anal microbial populations (microbiota) could affect acquisition of HIV or other conditions, especially among MSM, we profiled the microbiota of the anal canal, assessed its stability, and investigated associations with diversity and composition. DESIGN: Microbiota profiles in anal swabs collected from 76 MSM (52 in 1989, swab-1; 66 1-5 years later, swab-2) were compared by HIV status (25 HIV-positive), T-cell subsets, and questionnaire data. METHODS: Bacterial 16S rRNA genes were amplified, sequenced (Illumina MiSeq), and clustered into species-level operational taxonomic units (QIIME and Greengenes). Regression models and Wilcoxon tests were used for associations with alpha diversity (unique operational taxonomic units, Shannon's index). Composition was compared by Adonis (QIIME). RESULTS: Most anal bacteria were Firmicutes (mean 60.6%, range 21.1-91.1%) or Bacteroidetes (29.4%, 4.1-70.8%). Alpha diversity did not change between the two swabs (N = 42 pairs). In swab-2, HIV-positives had lower alpha diversity (P ≤ 0.04) and altered composition, with fewer Firmicutes and more Fusobacteria taxa (P ≤ 0.03), not completely attributable to very low CD4(+) cell count (median 232 cells/μl), prior AIDS clinical diagnosis (N = 17), or trimethoprim-sulfamethoxazole use (N = 6). Similar but weaker differences were observed in swab-1 (HIV-positive median 580 CD4(+) cells/μl; no trimethoprim-sulfamethoxazole). Associations with T-cell subsets, smoking, and sexual practices were null or inconsistent. CONCLUSIONS: The anal microbiota of MSM was relatively stable over 1-5 years. However, with uncontrolled, advanced HIV infection, the microbiota had altered composition and reduced diversity partially attributable to antibiotics. Investigations of microbial community associations with other immune perturbations and clinical abnormalities are needed.
Authors: Susan A Tuddenham; Wei Li A Koay; Ni Zhao; James R White; Khalil G Ghanem; Cynthia L Sears Journal: Clin Infect Dis Date: 2020-02-03 Impact factor: 9.079
Authors: J F Vázquez-Castellanos; S Serrano-Villar; A Latorre; A Artacho; M L Ferrús; N Madrid; A Vallejo; T Sainz; J Martínez-Botas; S Ferrando-Martínez; M Vera; F Dronda; M Leal; J Del Romero; S Moreno; V Estrada; M J Gosalbes; A Moya Journal: Mucosal Immunol Date: 2014-11-19 Impact factor: 7.313
Authors: Jennifer A Fulcher; Shehnaz K Hussain; Ryan Cook; Fan Li; Nicole H Tobin; Amy Ragsdale; Steven Shoptaw; Pamina M Gorbach; Grace M Aldrovandi Journal: J Infect Dis Date: 2018-10-05 Impact factor: 5.226
Authors: Ryan R Cook; Jennifer A Fulcher; Nicole H Tobin; Fan Li; David Lee; Marjan Javanbakht; Ron Brookmeyer; Steve Shoptaw; Robert Bolan; Grace M Aldrovandi; Pamina M Gorbach Journal: AIDS Date: 2019-04-01 Impact factor: 4.177
Authors: Liying Yang; Michael A Poles; Gene S Fisch; Yingfei Ma; Carlos Nossa; Joan A Phelan; Zhiheng Pei Journal: AIDS Date: 2016-01-02 Impact factor: 4.177